192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)

Autor:	D.A.A. Cameron, W. Jacot, T. Yamashita, M.J. Vidal Losada, P. Schmid, K.S. Lee, M. De Laurentiis, F. Zagouri, N.T. Ueno, A. Prat, N. Harbeck, R. Yerushalmi, Y-S. Lu, A. Gombos, C.M.A. Orbegoso, F-C. Cheng, L. Yung, R. Rajagopalan, J. Tsurutani, S. Modi
Rok vydání:	2023
Předmět:	Cancer Research Oncology
Zdroj:	ESMO Open. 8:101381
ISSN:	2059-7029
DOI:	10.1016/j.esmoop.2023.101381
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::21f5b9556c62ba6ba8b3a616de9f9425 https://doi.org/10.1016/j.esmoop.2023.101381 Zobrazit plný text záznamu